uniQure (NASDAQ:QURE) Receives “Neutral” Rating from Cantor Fitzgerald

Posted by Scott Moore on Mar 2nd, 2026

uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “neutral” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued on Monday, MarketBeat reports. They presently have a $9.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential downside of 9.31% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. William Blair restated a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Mizuho reduced their price target on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday, December 8th. Chardan Capital restated a “buy” rating and set a $53.00 price objective on shares of uniQure in a research report on Thursday, December 4th. Finally, Wolfe Research initiated coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Nine investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $52.42.

Read Our Latest Stock Analysis on QURE

uniQure Trading Down 36.5%

Shares of uniQure stock traded down $5.71 on Monday, hitting $9.92. The stock had a trading volume of 10,250,327 shares, compared to its average volume of 2,609,414. uniQure has a one year low of $7.76 and a one year high of $71.50. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock’s 50-day simple moving average is $23.46 and its two-hundred day simple moving average is $29.80. The stock has a market cap of $618.19 million, a price-to-earnings ratio of -2.21 and a beta of 0.66.

uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, sell-side analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 12,378 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $295,339.08. Following the sale, the chief executive officer owned 639,076 shares of the company’s stock, valued at $15,248,353.36. This trade represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christian Klemt sold 6,217 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the sale, the chief financial officer directly owned 211,513 shares of the company’s stock, valued at approximately $5,046,700.18. The trade was a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 50,598 shares of company stock worth $1,248,588 over the last three months. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors have recently modified their holdings of the company. Swiss National Bank acquired a new position in shares of uniQure during the 2nd quarter worth about $1,080,000. Sanders Morris Harris LLC bought a new position in uniQure in the third quarter valued at approximately $5,081,000. JPMorgan Chase & Co. increased its position in shares of uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. Aberdeen Group plc raised its stake in shares of uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of uniQure in the 2nd quarter valued at approximately $872,000. 78.83% of the stock is currently owned by institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

Positive Sentiment: uniQure reported Q4 EPS of ($0.56) which beat the consensus loss (~$0.93) and posted revenue of $5.57M (above estimates), showing somewhat better near‑term operating results than expectations. uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Neutral Sentiment: Company published full 2025 results and a corporate update and said it held a Type A meeting with the FDA and is evaluating Phase III development considerations; uniQure plans to request a follow‑up Type B meeting in Q2 to clarify next steps. uniQure Announces 2025 Financial Results and Provides Recent Company Updates
Neutral Sentiment: Market commentary pieces are reassessing uniQure’s valuation and outlook given the new regulatory focus; these analyses may increase trading volume and volatility as investors digest longer approval timelines. Assessing uniQure (QURE) After Sharp Share Price Slide And Gene Therapy Regulatory Focus
Negative Sentiment: FDA told uniQure its AMT‑130 early‑to‑mid stage data are insufficient to support a marketing application and urged a new randomized trial for the Huntington’s disease gene therapy — a major setback that will likely delay approval, increase development cost and push out potential revenue. FDA tells UniQure study data insufficient for brain disorder therapy application
Negative Sentiment: News outlets report the FDA decision sent QURE shares plunging (reports of ~40–45% premarket declines), reflecting investor concern about a materially longer path to commercialization for AMT‑130. uniQure Stock Plunges 40% After FDA Shocker
Negative Sentiment: Multiple securities‑class action lawsuits and law‑firm solicitations allege disclosure failures tied to AMT‑130; ongoing litigation increases legal risk and could be a drag on investor sentiment and resources. uniQure N.V. Sued for Securities Law Violations

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.